Celltrion to Conduct Trial of Remsima as COVID-19 Therapeutics in UK
Celltrion Healthcare announced on Wednesday that it would commence clinical trials of Remsima, an anti-inflammatory biosimilar, on COVID-19 patients this month ...
Celltrion Healthcare announced on Wednesday that it would commence clinical trials of Remsima, an anti-inflammatory biosimilar, on COVID-19 patients this month ...
Celltrion, South Korea’s leading biosimilar developer, said it doubled its efforts to create a super-fast test kit designed to identify ...
